As the cell therapy commercialization partner of a 5-year Department of Defense program to manufacture on-demand blood products, Safi Biotherapeutics and its collaborators are working to ‘crack the code’ of Cell Therapy 2.0 challenges of manufacturing at appropriate scale, high consistency of product, and economically viable cost of goods by integrating world-leading expertise in blood stem cell expansion, bioprocessing optimization, manufacturing scale-up and cryostorage.
Lead development programs for manufactured, on-demand cell therapy products include red blood cells for trauma, tailored red blood cells for specific transfusions (e.g. sickle cell disease).
The co-founders and leadership team at Safi Biotherapeutics bring experience in ex vivo human blood cell development, biologic and pharmaceutical manufacturing, pre-clinical and clinical development, and regulatory submissions.